Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ANIX
stocks logo

ANIX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.083
-7.41%
--
--
-0.095
-5%
--
--
-0.095
+5.56%
Estimates Revision
The market is revising No Change the revenue expectations for Anixa Biosciences, Inc. (ANIX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 59.60%.
EPS Estimates for FY2025
Revise Downward
down Image
-2.73%
In Past 3 Month
Stock Price
Go Up
up Image
+59.60%
In Past 3 Month
Wall Street analysts forecast ANIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANIX is 10.50 USD with a low forecast of 7.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast ANIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANIX is 10.50 USD with a low forecast of 7.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.740
sliders
Low
7.00
Averages
10.50
High
14.00
Current: 4.740
sliders
Low
7.00
Averages
10.50
High
14.00
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$10
2025-04-10
Reason
D. Boral Capital
Jason Kolbert
Price Target
$10
2025-04-10
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$10
2025-03-26
Reason
D. Boral Capital
Jason Kolbert
Price Target
$10
2025-03-26
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$7
2025-03-25
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$7
2025-03-25
Reiterates
Strong Buy
Reason
Maxim Group
Jason McCarthy
Strong Buy
Initiates
$10
2025-03-21
Reason
Maxim Group
Jason McCarthy
Price Target
$10
2025-03-21
Initiates
Strong Buy
Reason
Maxim initiated coverage of Anixa Biosciences with a Buy rating and $10 price target.
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$7
2025-02-18
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$7
2025-02-18
Reiterates
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$10
2025-01-22
Reason
D. Boral Capital
Jason Kolbert
Price Target
$10
2025-01-22
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Anixa Biosciences Inc (ANIX.O) is -12.87, compared to its 5-year average forward P/E of -9.01. For a more detailed relative valuation and DCF analysis to assess Anixa Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.01
Current PE
-12.87
Overvalued PE
-6.33
Undervalued PE
-11.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.95
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.52
Undervalued EV/EBITDA
-6.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
38.46
Current PS
0.00
Overvalued PS
187.81
Undervalued PS
-110.89
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 288.42% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 288.42% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ANIX News & Events

Events Timeline

(ET)
2025-11-17
08:17:58
Anixa Biosciences' CAR-T Therapy Receives WHO Approval for Non-Proprietary Name
select
2025-11-12 (ET)
2025-11-12
09:03:13
Anixa Biosciences Receives Patent for Breast Cancer Vaccine Technology
select
2025-11-05 (ET)
2025-11-05
08:56:51
Anixa Biosciences Completes Data Transfer with Cleveland Clinic
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-17Newsfilter
Anixa Biosciences Receives WHO Approval for International Non-Proprietary Name of CAR-T Therapy, Signifying Major Step Towards Global Recognition and Future Market Launch

  • Approval of Non-Proprietary Name: Anixa Biosciences announced that the WHO's INN Expert Committee approved "liraltagene autoleucel" as the non-proprietary name for its CAR-T therapy targeting recurrent ovarian cancer, marking a significant step towards commercialization.

  • Ongoing Clinical Trials: The company is currently conducting a Phase 1 trial of liraltagene autoleucel in partnership with Moffitt Cancer Center, focusing on safety and clinical activity in women with recurrent ovarian cancer who have not responded to previous treatments.

  • Unique CAR-T Technology: Liraltagene autoleucel utilizes a novel chimeric endocrine receptor-T cell (CER-T) technology that targets the follicle-stimulating hormone receptor (FSHR), which is expressed on ovarian cells and certain cancer cells.

  • Anixa's Broader Portfolio: Anixa is a clinical-stage biotechnology company with a focus on cancer treatment and prevention, collaborating with leading research institutions to develop innovative therapies, including vaccines for breast and ovarian cancer.

[object Object]
Preview
1.0
11-13Newsfilter
Water Tower Research Releases Statement on Technical Issues During Anixa Biosciences Fireside Chat

  • Technical Issue During Event: Water Tower Research experienced a technical disruption during a live Fireside Chat with Anixa Biosciences on November 11, 2025, which interrupted the streaming service.

  • Event Replay Available: The session was fully recorded and is now accessible for on-demand viewing through a provided link.

  • Apology and Resolution: Shawn Severson, CEO of Water Tower Research, apologized for the inconvenience and confirmed that the technical issue has been resolved to prevent future disruptions.

  • About Water Tower Research: The organization focuses on modernizing investor engagement through research-driven communications, providing equal access to high-quality company research for both institutional and retail investors.

[object Object]
Preview
9.0
11-12PRnewswire
Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s

  • Patent Issuance: Anixa Biosciences will receive U.S. Patent Number 12,472,205 on November 18, 2025, which covers innovative methods for inducing an immune response to the α-lactalbumin protein, a target for breast cancer immunoprevention.

  • Vaccine Development: The breast cancer vaccine, developed in collaboration with Cleveland Clinic, aims to stimulate the immune system to identify and eliminate cancer cells expressing α-lactalbumin while minimizing effects on normal tissue.

  • Market Need: With over 297,000 new cases of invasive breast cancer projected in the U.S. for 2025 and no FDA-approved vaccine currently available, Anixa's vaccine represents a significant advancement in preventive oncology.

  • Company Overview: Anixa is a clinical-stage biotechnology firm focused on cancer treatment and prevention, with a diverse portfolio that includes vaccines for breast and ovarian cancer, developed in partnership with leading research institutions.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Anixa Biosciences Inc (ANIX) stock price today?

The current price of ANIX is 4.74 USD — it has decreased -2.27 % in the last trading day.

arrow icon

What is Anixa Biosciences Inc (ANIX)'s business?

Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. The Company's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. The Company is engaged in the development of vaccines for the treatment or prevention of triple negative breast cancer and other breast cancers which express the a-lactalbumin protein. Its vaccine technologies are focused on immunizing against retired proteins that have been found to be expressed in certain forms of cancer.

arrow icon

What is the price predicton of ANIX Stock?

Wall Street analysts forecast ANIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANIX is 10.50 USD with a low forecast of 7.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Anixa Biosciences Inc (ANIX)'s revenue for the last quarter?

Anixa Biosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Anixa Biosciences Inc (ANIX)'s earnings per share (EPS) for the last quarter?

Anixa Biosciences Inc. EPS for the last quarter amounts to -0.07 USD, decreased -30.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Anixa Biosciences Inc (ANIX)'s fundamentals?

The market is revising No Change the revenue expectations for Anixa Biosciences, Inc. (ANIX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 59.60%.
arrow icon

How many employees does Anixa Biosciences Inc (ANIX). have?

Anixa Biosciences Inc (ANIX) has 5 emplpoyees as of December 05 2025.

arrow icon

What is Anixa Biosciences Inc (ANIX) market cap?

Today ANIX has the market capitalization of 156.03M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free